Taslima Zaman, Ahsanul Haq, Rahnuma Ahmad, Susmita Sinha, Kona Chowdhury, Sultana Parvin, Mostofa Imran, Zaman U Humayra, Santosh Kumar, Mainul Haque
Background Helicobacter pylori infection has been identified to cause constantly recurring inflammation, leading to gastrointestinal tract disorders, including carcinoma. The standard triple therapy (STT), used to eradicate H. pylori, includes two antimicrobials and a proton pump inhibitor for two weeks. Other drug regimens have also been developed since H. pylori exhibits antimicrobial resistance. These regimens, including probiotics, have been shown to lower adverse drug reactions (ADR), improve drug adherence, exert bacteriostatic effect, and reduce inflammation...
March 2024: Curēus